Could DermTech Be a Millionaire-Maker Stock?
DermTech (NASDAQ: DMTK) has the potential to be a truly disruptive genomics company, one that could change dermatology entirely. And investors like the stock -- DermTech's shares are up more than 400% over the past year.
Skin cancers are the most prevalent form of cancer, affecting one in five Americans by the age of 70, according to the Skin Cancer Foundation. The most common forms of skin cancer are basil cell carcinoma and squamous cell carcinoma, but the most deadly is melanoma, according to a American Cancer Society report, which estimated that of the more than 100,000 people who were diagnosed with melanomas in the United States in 2020, 6,850 of them died from the disease. DermTech is looking to lower those numbers. If it's succesful, it might reward shareholders in the process.
Image source: Getty Images.
Source Fool.com
